QURE Jack Kaye sells $174K worth of shares
Feb 01, 2026, 5:35 AM
0.00%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
Jack Kaye sold 6,390 shares of QURE on 9 January at $27.28 per share, worth a total of $174K. They now own 20,439 QURE shares, or a 24% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.